<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324558</url>
  </required_header>
  <id_info>
    <org_study_id>ICT-BEM-2004-01</org_study_id>
    <secondary_id>2004-004722-27 (Nº EudraCT)</secondary_id>
    <nct_id>NCT00324558</nct_id>
  </id_info>
  <brief_title>Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)</brief_title>
  <official_title>Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective:

      To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26
      weeks, starting on the first day of chemotherapy (CT), delays tumoral spread and increases
      progression-free survival.

      Secondary objectives:

      To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26
      weeks, starting with the onset of chemotherapy, increases global survival, improving the
      response rates to treatment with CT + RT (radiotherapy) and reduces the incidence of venous
      thromboembolism (VTE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is clinical evidence indicative of the beneficial effects of heparin in the evolution
      of patients with cancer. Apart from the studies that in an indirect way demonstrated an
      increase in the survival of oncological patients who, because of presenting a venous
      thromboembolism episode, were treated with low molecular weight heparin (LMWH) in comparison
      with those treated with non-fractionated heparin; direct actions were also demonstrated from
      the use of heparin in the survival and tumour progression. The administration of LMWH
      together with Chemotherapy has been proved to increase the survival of patients diagnosed of
      cancer of the pancreas in relation to those only treated with chemotherapy. An increase in
      the global survival of advanced solid tumours, with no thromboembolic disease,has also been
      showed.

      All this suggests that an improvement in the survival of patients is observed when heparin is
      added to the usual anti-tumour treatment, especially to those without spread disease, and
      this effect seems to be independent of the protection against the thromboembolic
      complications.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor stopped due to difficulties to recruit 130 patients required by protocol
  </why_stopped>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy: progression-free survival in months (measurements of the size of the effect will be done using the Kaplan Meier method and the difference between the means of this time)</measure>
    <time_frame>efficacy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>safety: will be the incidence, during randomized treatment period (from day 1 to the last day of treatment + 7 days), of major bleedings.</measure>
    <time_frame>safety</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Carcinoma, Small Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bemiparin 3,500 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bemiparin</intervention_name>
    <description>subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years old or older, of either sex, with a diagnosis of limited small cell
             lung cancer.

          2. Patients with an ECOG functional state less than or equal to 2.

          3. Informed consent to participate in the study.

          4. Patients with a platelet count above 100,000/microlitre with no hemorrhagic
             symptomatology.

        Exclusion Criteria:

          1. Curative or palliative surgery as the initial treatment of their neoplastic condition.

          2. Patients with an active hemorrhage in the past two months, organic lesions susceptible
             to bleeding (e.g. active peptic ulcer, hemorrhagic cerebrovascular accident,
             aneurysms), history of clinically evident hemorrhagic episodes, major surgery in the
             past month, outstanding clinically hemoptysis or an increased risk of bleeding due to
             any homeostatic alteration that contraindicates anticoagulant therapy.

          3. Known hypersensitivity to LMWH, heparin or substances of porcine origin.

          4. Patients with hypersensitivity to the chemotherapeutic agents used in this protocol
             that makes it impossible to use the antitumoral regime indicated in this protocol
             (cisplatin or carboplatin and etoposide), i.e. hypersensitivity to cisplatin and
             carboplatin or hypersensitivity to etoposide.

          5. Patients with congenital or acquired bleeding diathesis.

          6. Damage to/ or surgical interventions of the central nervous system, eyes and ears
             within the past 6 months.

          7. Acute bacterial endocarditis or slow endocarditis.

          8. Patients with a history of heparin-associated thrombocytopenia or with a current
             platelet count &lt; 100,000/mm3

          9. Patients with severe renal failure (serum creatinine over 2 mg/dl) or hepatic
             insufficiency (with values of AST and/or ALT &gt; 5 times the normal value established in
             the reference range of the local hospital laboratory).

         10. Severe arterial hypertension (systolic blood pressure over 200 mmHg and/or diastolic
             blood pressure above 120 mmHg).

         11. Women who are pregnant or breast-feeding, or with the possibility of becoming pregnant
             during the study.

         12. Patients with suspected inability/or inability to comply with treatment and/or
             complete the study.

         13. Patients who are participating in another clinical trial or have done so in the past
             30 days.

         14. Patients with a life expectancy less than 3 months.

         15. Patients on treatment with anticoagulants or who have been on treatment during three
             months before the diagnosis of the tumor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Gúrpide, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Gonzalez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Morales Meseguer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillermo López, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopspital de Cruces, Baracaldo (Vizcaya)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>César Rodríguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan C. Torrego, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Río Hortega</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Gómez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL LA FE VALENCIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Font, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isidoro C. Barneto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Reina Sofia (Córdoba)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Lorenzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Puerto Real (Cádiz)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dolores Isla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Lozano Blesa (Zaragoza)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Rocha, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clínica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bartolomeu Massuti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Alicante</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Galán Brotons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Sagunto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Blasco Cordellat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan J. Bretón, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Carlos Haya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Bover Barceló, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Llàtzer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nuria Viñolas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i Provincial de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cádiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <state>Córdoba</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Son Ferriol</city>
        <state>Islas Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Puerto de Sagunto</city>
        <state>Valencia</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provicial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2006</study_first_submitted>
  <study_first_submitted_qc>May 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2006</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bemiparin</keyword>
  <keyword>small cell lung carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

